Successive therapies may extend survival in AIPC. Interview by Alice Goodman.
Petrylak
Daniel
D
D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000077143:Docetaxel; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D043823:Taxoids / Q000276:immunology / Q000627:therapeutic use; D014020:Tissue Extracts / Q000276:immunology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D043823:Taxoids; D014020:Tissue Extracts; D000077143:Docetaxel; C511774:sipuleucel-T